Full-Time
Updated on 8/10/2026
Medical device maker advancing therapies
$164.8k - $247.2k/yr
H1B Sponsorship Available
Mounds View, MN, USA
Hybrid
At least four days on-site per week are required.
Bachelor's, Master's, PhD
See people who can refer or advise you
Medtronic makes medical devices and therapies to treat chronic diseases, including implantables, sensors, and diabetes management tools. Its devices interact with the body to regulate or monitor functions, such as pacemakers delivering heart stimulation and neuromodulation devices sending electrical signals. The company differentiates itself through a long history of device development and a broad portfolio, expanded via acquisitions to access new technologies and markets. Its goal is to improve patient health outcomes by providing integrated medical technologies that help manage chronic conditions.
Company Size
10,001+
Company Stage
IPO
Headquarters
Fridley, Minnesota
Founded
1949
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Health Savings Account/Flexible Spending Account
Unlimited Paid Time Off
Paid Vacation
Paid Sick Leave
Paid Holidays
401(k) Retirement Plan
401(k) Company Match
Employee Stock Purchase Plan
Employee Assistance Program
Wellness Program
Medtronic and Intuitive Surgical, two medical device leaders, have underperformed this year due to sector weakness and company-specific challenges. However, both show potential for recovery. Medtronic's fourth-quarter revenue rose 9.9% to $9.8 billion, though adjusted earnings per share fell 4.3% to $1.55 due to higher costs, including tariffs. The company posted its highest annual revenue growth in a decade, driven partly by its Pulse Field Ablation franchise. Medtronic recently received FDA clearance for its Hugo robotic-assisted surgery system for urologic procedures, positioning it to compete in the underpenetrated robotic surgery market. The company plans to spin off its lower-margin diabetes care division, which should improve margins. With a 3.4% forward dividend yield and 49 consecutive years of payout increases, Medtronic appeals to income-focused investors.
Medtronic has received expanded CE Mark approval for its Affera Mapping and Ablation System with Sphere-9 Catheter to treat ventricular arrhythmias, including ventricular tachycardia and premature ventricular complexes. The Sphere-9 catheter is the first all-in-one mapping and ablation, large-tip focal, dual-energy catheter CE marked for ventricular ablation. The US Food and Drug Administration granted Breakthrough Device Designation for the Sphere-9 catheter, providing an expedited regulatory pathway. The Sphere VT pivotal trial is now enrolling patients to support future US approval. The system combines pulsed field and radiofrequency ablation with high-definition mapping in a single catheter. Medtronic says the technology addresses an unmet need in treating ventricular arrhythmias, where outcomes have remained suboptimal with limited recent innovation in ablation tools.
Medtronic invests in CoreMap's oversubscribed $37m Series C round. July 31, 2026 The funds raised will enable CoreMap to develop more precise data-driven tools to address atrial fibrillation ablation. Read more: Medtronic invests in CoreMap's oversubscribed $37m Series C round.
CoreMap, a medical technology company developing tools for atrial fibrillation (AF) treatment, has closed an oversubscribed $37 million Series C financing round. Medtronic led the investment, with participation from existing and new investors. The Burlington, Massachusetts-based company will use the funding to accelerate development of its next-generation AF mapping platform. CoreMap's technology uses high-density mapping and advanced data analytics to provide physicians with more precise guidance for AF ablation procedures. Chief executive officer Sarah Kalil said the investment enables CoreMap to pursue its vision of providing electrophysiologists with clearer understanding of AF for more targeted, personalised treatment. Chris Eso, global head of corporate and business development at Medtronic, noted that CoreMap is addressing critical unmet needs in AF treatment with differentiated technology and strong clinical support. Founded in 2016, CoreMap develops electrophysiology mapping systems based on large datasets of electrical activation data.
Medtronic continues assembly of industry's "broadest" pain therapy portfolio. Medtronic formally launched ViaVerte at ASPN 2026, with its $650m acquisition of SPR Therapeutics completing at the meeting's outset on 16 July. Bolstered by a recent $650m deal and a new device launch, Medtronic's pain therapy product lineup is going from strength to strength. Medtronic's completed acquisition of SPR Therapeutics this July, along with its recent formal rollout of the ViaVerte basal nerve ablation system, avails the medtech giant of the "broadest pain therapy portfolio in the industry", a Medtronic executive has asserted. ViaVerte is a basivertebral nerve ablation (BVNA) system that delivers radiofrequency (RF) ablation to destroy the small nerve within the vertebral body that is responsible for transmitting pain signals associated with chronic lower-back pain. Originally developed by Merit Medical, Medtronic signed a distribution deal for the system in March 2026. Following the agreement, Medtronic formally launched ViaVerte, which secured US Food and Drug Administration (FDA) clearance in March 2026, at the 2026 American Society of Pain and Neuroscience (ASPN) meeting, which took place 16-19 July in Miami. Meanwhile, Medtronic completed its $650m acquisition of SPR Therapeutics on 16 July. The Ohio-based company's lead product is SPRINT, a peripheral nerve stimulation (PNS) system for addressing chronic pain and expands Medtronic's existing chronic pain lineup. According to GlobalData analysis, the global neuromodulation device market is projected to reach a valuation of over $13bn in 2035, up from around $6.8bn in 2025. Ashwini Sharan, CMO at Medtronic Neuromodulation, tells Medical Device Network the addition of SPR's core product and ViaVerte strengthens what the company believes is the "broadest pain therapy portfolio in the industry" while also reinforcing Medtronic's ability to serve patients of pain care "with evidence-based, non-opioid treatment options". Sharan continues: "The launch of ViaVerte, together with its acquisition of SPR Therapeutics, reflects its commitment to expanding patient access to innovative, minimally invasive pain therapies. "ViaVerte complements our existing pain interventions portfolio by giving physicians an additional option for appropriately selected patients with vertebrogenic chronic low back pain, while SPRINT expands our ability to address both chronic and acute pain through short-term peripheral nerve stimulation." Regarding ViaVerte's rollout in the US, Sharan says the company is taking a "thoughtful, phased approach to commercialisation" in order to satisfy dictates around the BVNA system, including clinical support and patient access. "Our focus is on ensuring clinicians have the training and resources needed to successfully integrate the therapy into practice while expanding access responsibly. As adoption continues to grow, we'll build on our commercial infrastructure and physician-support network to broaden availability," Sharan explains. "Whether it's for ViaVerte for vertebrogenic pain or SPRINT for chronic and acute pain, we're focused on expanding access to innovative, non-opioid therapies that support individualised treatment decisions and meaningful improvements in patients' quality of life," he concludes. Give your business an edge with its leading industry insights.